Top Industry Leaders in the Liquid Biopsy Market
*Disclaimer: List of key companies in no particular orderLatest Liquid biopsy Companies Update
-
Mar 2023: To increase the accessibility and affordability of oncology homologous recombination deficiency (HRD) testing in the United States, Illumina Inc., an international innovator in DNA sequencing and array-based technologies, and Myriad Genetics Inc., an industry innovator in genetic testing and precision medicine, announced the expansion of their strategic partnership. Illumina TruSightTM Oncology 500 HRD (TSO 500 HRD), a test intended primarily for research purposes, is now accessible in the US per the agreement. The strengthened collaboration also creates a special companion diagnostic (CDx) partnership for the pharmaceutical sector, enabling greater clinical study for gene-based, targeted medicines. The TSO 500 HRD research test combines the TSO 500 pan-cancer test from Illumina with Myriad's MyChoice® CDx HRD technology, the industry's gold standard. The test was created in collaboration with Myriad Genetics and Merck (also known as MSD outside of the US and Canada). The initial collaboration between Myriad and Illumina resulted in the global launch of Illumina's combination HRD and TSO 500 solution in June 2022, except for the US and Japan.
-
Sep 2023: A leading commercial-stage precision diagnostics organization, MDxHealth SA, announced a research partnership with the University of Oxford to investigate the relationship between prostate cancer progression after treatment for localized prostate cancer and the Genomic Prostate Score (GPS) test. In the commercial stage, Mdxhealth is a precision diagnostics company that offers useful molecular data to tailor patient diagnosis and care. The Company's tests aid doctors in diagnosing and prognosis urologic malignancies and other urologic disorders and are based on proprietary genomic, epigenetic (methylation), and other molecular technologies.
List of Liquid biopsy Key companies in the market
- Hoffmann-La Roche Ltd. (Switzerland)
- Myriad Genetics, Inc. (US)
- QIAGEN (Netherlands)
- Thermo Fisher Scientific, Inc. (US)
- Guardant Health, Inc. (US)
- MDxHealth SA (Belgium)
- Exact Sciences Corporation (US)
- Illumina Inc. (US)
- Sysmex Inostics (US)
- Biocept, Inc. (US)
- NeoGenomics, Inc. (US)
- ANGLE plc (UK)
- Menarini-Silicon Biosystems (Italy)
- Vortex Biosciences, Inc. (US)
- Exosome Diagnostics, Inc. (US)
- Agena Bioscience, Inc. (US)
- MedGenome Inc. (US)
- Epigenomics AG (Germany)
- Personal Genome Diagnostics, Inc. (US)